GCP
RLAY icon

GSA Capital Partners’s Relay Therapeutics RLAY Stock Holding History

GSA Capital Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-129,422
Closed -$676K – 2023
2025
Q3 		$676K Buy
129,422
+48,860
+61% +$186K 0.06% 649
2025
Q2 		$279K Buy
80,562
+28,083
+54% +$83.5K 0.02% 1304
2025
Q1 		$137K Sell
52,479
-77,469
-60% -$304K 0.01% 1468
2024
Q4 		$535K Buy
129,948
+114,541
+743% +$623K 0.04% 841
2024
Q3 		$109K Sell
15,407
-82,997
-84% -$620K 0.01% 1480
2024
Q2 		$642K Buy
98,404
+70,983
+259% +$485K 0.04% 802
2024
Q1 		$228K Buy
27,421
+5,499
+25% +$53.6K 0.02% 1347
2023
Q4 		$241K Sell
21,922
-90,179
-80% -$761K 0.02% 1229
2023
Q3 		$943K Buy
112,101
+52,712
+89% +$567K 0.08% 432
2023
Q2 		$746K Buy
+59,389
New +$739K 0.07% 482
2022
Q3 		– Sell
-178,593
Closed -$2.99M – 1813
2022
Q2 		$2.99M Buy
+178,593
New +$3.83M 0.45% 2

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's RLAY Position: Q4 2025 in Review

GSA Capital Partners sold out of Relay Therapeutics (RLAY) in Q4 2025, closing a stake of 129,422 shares — an estimated $676K sold.

GSA Capital Partners first reported a position in RLAY in Q2 2022 and held it in 11 quarters. The position peaked at $2.99M in Q2 2022. 227 funds tracked by Wall St. Rank hold RLAY as of Q4 2025.

  • GSA Capital Partners reported no remaining Relay Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 129,422 Relay Therapeutics shares in Q4 2025, an estimated $676K.
  • GSA Capital Partners first reported a position in Relay Therapeutics in Q2 2022 and held it in 11 quarters.
  • GSA Capital Partners's Relay Therapeutics position peaked at $2.99M in Q2 2022.
  • 227 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.